Incidence of Hypertension and Blood Pressure Changes in Persons With Human Immunodeficiency Virus at High Risk for Cardiovascular Disease Switching From Boosted Protease Inhibitors to Dolutegravir: A Post-hoc Analysis of the 96-week Randomised NEAT-022 Trial
Clinical Infectious Diseases · 05.10.2023 · 77 (7) · 991-1009
DOI: 10.1093/cid/ciad297 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Clinical Infectious Diseases, online erschienen am 19.05.2023. Verfasst von Abiu Sempere und 24 weiteren Autor:innen. Beteiligte Einrichtung: Hospital Clínic-IDIBAPS, University of Barcelona, Barcelona, Spain. Hauptthemen laut MEDLINE: Heterocyclic Compounds, 3-Ring, HIV Infections, Hypertension, Blood Pressure. Die Arbeit wurde bisher 25-mal zitiert (Crossref) und nennt 33 Literaturangaben. Gefördert von: NEAT-ID Foundation, St Stephen's Aids Trust, ViiV Healthcare.
Abstract (Originalsprache)
Background
Integrase inhibitors have been recently linked to a higher risk for hypertension. In NEAT022 randomized trial, virologically suppressed persons with human immunodeficiency virus (HIV, PWH) with high cardiovascular risk switched from protease inhibitors to dolutegravir either immediately (DTG-I) or after 48 weeks (DTG-D).
Methods
Primary endpoint was incident hypertension at 48 weeks. Secondary endpoints were changes in systolic (SBP) and diastolic (DBP) blood pressure; adverse events and discontinuations associated with high blood pressure; and factors associated with incident hypertension.
Results
At baseline, 191 (46.4%) participants had hypertension and 24 persons without hypertension were receiving antihypertensive medications for other reasons. In the 197 PWH (n = 98, DTG-I arm; n = 99, DTG-D arm) without hypertension or antihypertensive agents at baseline, incidence rates per 100 person-years were 40.3 and 36.3 (DTG-I) and 34.7 and 52.0 (DTG-D) at 48 (P = .5755) and 96 (P = .2347) weeks. SBP or DBP changes did not differed between arms. DBP (mean, 95% confidence interval) significantly increased in both DTG-I (+2.78 mmHg [1.07–4.50], P = .0016) and DTG-D (+2.29 mmHg [0.35–4.23], P = .0211) arms in the first 48 weeks of exposure to dolutegravir. Four (3 under dolutegravir, 1 under protease inhibitors) participants discontinued study drugs due to adverse events associated with high blood pressure. Classical factors, but not treatment arm, were independently associated with incident hypertension.
Conclusions
PWH at high risk for cardiovascular disease showed high rates of hypertension at baseline and after 96 weeks. Switching to dolutegravir did not negatively impact on the incidence of hypertension or blood pressure changes relative to continuing protease inhibitors.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Hospital Clínic-IDIBAPS, University of Barcelona, Barcelona, Spain.
- CIBER de Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III, Madrid, Spain.
- Département d'Epidémiologie, Sorbonne Université, INSERM, Institut Pierre Louis d'Épidémiologie et de Santé Publique, Paris, France.
- Mortimer Market Centre, Central & North West London National Health Service (NHS) Foundation Trust, London, United Kingdom.
- Ospedale Luigi Sacco, Università degli Studi, Milano, Italy.
- Hospital de Sant Pau, Barcelona, Spain.
Förderung
- NEAT-ID Foundation
- St Stephen's Aids Trust
- ViiV Healthcare
- CIBERINFEC -Consorcio Centro de Investigación Biomédica en Red
- Instituto de Salud Carlos III
- Ministerio de Ciencia e Innovación and Unión Europea-NextGenerationEU
- Spanish AIDS Research Network
- ISCIII- Subdirección General de Evaluación
Zitieren
APA
Sempere, A., Assoumou, L., González-Cordón, A., Waters, L., Rusconi, S., Domingo, P., Gompels, M., de Wit, S., Raffi, F., Stephan, C., Masiá, M., Rockstroh, J., Katlama, C., Behrens, G. M. N., Moyle, G., Johnson, M., Fox, J., Stellbrink, H. J., Guaraldi, G., …, & NEAT 022 Study Group (2023). Incidence of Hypertension and Blood Pressure Changes in Persons With Human Immunodeficiency Virus at High Risk for Cardiovascular Disease Switching From Boosted Protease Inhibitors to Dolutegravir: A Post-hoc Analysis of the 96-week Randomised NEAT-022 Trial. Clinical Infectious Diseases, 77(7), 991-1009. https://doi.org/10.1093/cid/ciad297
Vancouver
Sempere A, Assoumou L, González-Cordón A, Waters L, Rusconi S, Domingo P, et al. Incidence of Hypertension and Blood Pressure Changes in Persons With Human Immunodeficiency Virus at High Risk for Cardiovascular Disease Switching From Boosted Protease Inhibitors to Dolutegravir: A Post-hoc Analysis of the 96-week Randomised NEAT-022 Trial. Clinical Infectious Diseases. 2023;77(7):991-1009. doi:10.1093/cid/ciad297
BibTeX
@article{Sempere2023,
author = {Sempere, Abiu and Assoumou, Lambert and González-Cordón, Ana and Waters, Laura and Rusconi, Stefano and Domingo, Pere and Gompels, Mark and de Wit, Stephane and Raffi, François and Stephan, Christoph and Masiá, Mar and Rockstroh, Jürgen and Katlama, Christine and Behrens, Georg M N and Moyle, Graeme and Johnson, Margaret and Fox, Julie and Stellbrink, Hans-Jürgen and Guaraldi, Giovanni and Florence, Eric and Esser, Stefan and Gatell, José and Pozniak, Anton and Martínez, Esteban and NEAT 022 Study Group, NEAT 022 Study Group},
title = {Incidence of Hypertension and Blood Pressure Changes in Persons With Human Immunodeficiency Virus at High Risk for Cardiovascular Disease Switching From Boosted Protease Inhibitors to Dolutegravir: A Post-hoc Analysis of the 96-week Randomised NEAT-022 Trial},
journal = {Clinical Infectious Diseases},
year = {2023},
volume = {77},
number = {7},
pages = {991--1009},
doi = {10.1093/cid/ciad297}
}
EUVIMED